Dublin, Nov. 23, 2021 (GLOBE NEWSWIRE) -- The "Bioanalytical Testing Services Market Share, Size, Trends, Industry Analysis Report, By Molecule Type (Small Molecule, Large Molecule); By Test Type; By Workflow; By Region; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.
The global bioanalytical testing services market size is expected to reach $6.34 billion by 2028
Bioanalytical testing is the most crucial process involved in the process of drug discovery and development. Bioanalytical methods are employed in pharmacokinetics, bioequivalence, toxicology, pharmacology, and bioavailability studies in humans or animals for the quantitative analysis of drugs in biological samples such as plasma, serum, urine, or other biological systems.
Now, pharmacokinetic characterization of a novel chemical drug candidate is conducted from the initial process of drug discovery to the advanced stages of drug development. ADME/PK screening is used to study metabolism and absorption, and the testing is initially carried out in in-vitro systems. Still, however, in-vivo studies are carried out in later stages of pre-clinical development for definitive assessment of overall drug disposition.
In previous decades ADME/PK studies were carried out at later stages of clinical development. Hence, many new chemical entities failed at later development stages due to shortcomings in metabolism and PK. In-vitro approaches in ADME/PK at an earlier stage in the drug development process will minimize the failure of a drug candidate at later stages.
The development of innovative drugs in the market, the emergence of biosimilars, and increasing numbers of CROs across the globe are the primary driving force behind the growth of the global testing services market. Companies are also raising funds and going for acquisition and collaboration to develop and commercialize new bioanalytical platforms.
In January 2021, Adeptrix Corp raised Series A investment to accelerate its proprietary BAMS platform technology commercialization. The company has recently entered into many research partnerships to develop rapid and accurate COVID-19 diagnostics based on its Bead Assisted Mass Spectrometry.
During the same time, Nexelis acquired a GCLP-certified clinical bioanalytical laboratory owned by GSK Germany. The certified clinical bioanalytical laboratory has 80 scientists and analysts. Through a 5-year collaboration agreement, the team of Nexelis will now assist in the development of future vaccine candidates of GSK.
COVID-19 pandemic has further accelerated the growth of the global testing services market during the forecast period. Services companies are investing in bioanalytical platforms to develop new COVID-19 diagnostic testing and develop new drugs to combat the deadly pandemic that is wreaking havoc across the globe.
Bioanalytical Testing Services Market Dynamics
Drivers and Opportunities
Increasing outsourcing services
Rising investments in the sector
Restraints and Challenges
Efficacy and accuracy
Charles River Laboratories International
Pace Analytical Services LLC
Bioanalytical Testing Services, Molecule Type Outlook
Anti-Drug Antibody (ADA)
Other Large Molecule Tests
Bioanalytical Testing Services, Test Type Outlook
Absorption, Distribution, Metabolism, Excretion (ADME)
Bioanalytical Testing Services, Workflow Outlook
Liquid-liquid extraction (LLE)
Solid phase extraction (SPE)
Ligand Binding Assay
Nuclear magnetic resonance
Other Workflow Processes
Bioanalytical Testing Services, Regional Outlook
Central & South America
Middle East & Africa
For more information about this report visit https://www.researchandmarkets.com/r/5eax7b
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900